Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.

202040 citationsJournal Article

Authors

Ш. Ф. Эрдес · VA Nasonova Scientific Research Institute of Rheumatology

Е. Л. Насонов · VA Nasonova Scientific Research Institute of Rheumatology

Е. В. Кундер

Andrey Pristrom

Nikolay Soroka · Belarusian State Medical University

P. А. Shesternya · Krasnoyarsk State Medical University

Tatiana Dubinina · VA Nasonova Scientific Research Institute of Rheumatology

Abstract

The data obtained demonstrate the efficacy and favourable safety profile of NTK in active AS. Clinical development of NTK will be continued in a phase 3 trial aimed to evaluate the efficacy of 1-year treatment with NTK 120 mg in patients with AS.

Topics & Keywords

Psoriasis: Treatment and Pathogenesis Spondyloarthritis Studies and Treatments Rheumatoid Arthritis Research and Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 38, Issue 1, pp. 27-34

Field-Weighted Citation Impact: 2.58